Clinical and demographic characteristics and treatment outcomes of patients with HR+/HER2– advanced breast cancer receiving ribociclib in standard clinical practice in Russia: interim results of the PROSPERITY study

Objective. To describe the clinical and demographic characteristics and to assess the effectiveness and safety of ribociclib combined with endocrine therapy (ET) in patients with HR+/HER2– advanced breast cancer (ABC) in Russian clinical practice settings, as part of the PROSPERITY observational study. Materials and methods. At the date of the interim analysis (October 31, 2024), the PROSPERITY study had enrolled 2.390 patients with HR+/HER2– ABC receiving ribociclib, alpelisib, ET, or chemotherapy as part of standard clinical practice in Russia. The ribociclib group comprised 1.468 patients (61.4% of the total cohort). This article analyzes clinical and demographic characteristics, time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS), time to chemotherapy (TTC), and the safety profile of ribociclib. The index date was defined as the date of initiation of ribociclib therapy during the study enrollment period. Results. The median age of patients in the ribociclib arm was 59.0 years. The majority of patients received ribociclib as first-line (63.0%) or second-line (21.9%) therapy. The median TTF was 17.2 months (95% CI 16.1–18.4), and the median PFS was 20.3 months (95% CI 18.8–21.5). Median PFS was 24.3 months for first-line therapy, 16.0 months for second-line, 13.4 months for third-line, and 8.6 months for fourth and subsequent lines. Median OS and median TTC were not reached. Adverse events (AEs) were reported in 47.5% (723/1522) of patients; the most common were neutropenia (16.2%) and leukopenia (7.4%). The rate of treatment discontinuation due to AEs was low (5.9% of all patients in the ribociclib arm). Conclusion. The observational PROSPERITY study provided real-world data from Russia demonstrating ribociclib effectiveness and safety profiles generally comparable to results previously obtained in pivotal clinical trials.

Authors

Institutions

Publication Details

Journal
P A Herzen Journal of Oncology
Published
2026-10-30
DOI
https://doi.org/10.17116/onkolog20261505152
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Clinical and demographic characteristics and treatment outcomes of patients with HR+/HER2– advanced breast cancer receiving ribociclib in standard clinical practice in Russia: interim results of the PROSPERITY study

T.V. Vinogradova, Natalia E. Musaeva, Malkhaz Yu. Tsikoridze, Elena Babich et al.
3 links
P A Herzen Journal of Oncology
Advanced Breast Cancer Therapies
article

Clinical and demographic characteristics and treatment outcomes of patients with HR+/HER2– advanced breast cancer receiving ribociclib in standard clinical practice in Russia: interim results of the PROSPERITY study

T.V. Vinogradova, Natalia E. Musaeva, Malkhaz Yu. Tsikoridze, Elena Babich, Гармарник Татьяна Валерьевна, Liubov Yu Vladimirova, Константин Викторович Меньшиков, Елена Владимировна Артамонова, Н А Знаткова, Россоха Елена Ивановна, Роман Сергеевич Жихорев, Svetlana A. Orlova, Никита Михайлович Волков, Дергунов Александр Сергеевич, А. А. Аксарин, Шкрадюк Александр Викторович, Elena Igorevna Kovalenko, Илья Анатольевич Покатаев, R. P. Litvinov, Lyudmila Zhukova, А. В. Султанбаев, S. V. Averyanova, Воронкова Лия Михайловна, Белогорцев Игорь Олегович, Ya. A. Tyugina, Denis Yu. Yukalchuk, Мария Ивановна Антошкина, Надежда Витальевна Леушина, O.V. Mironov, A.V. Vasilevskaya, O.N. Aleksandrova
article en

Abstract

Objective. To describe the clinical and demographic characteristics and to assess the effectiveness and safety of ribociclib combined with endocrine therapy (ET) in patients with HR+/HER2– advanced breast cancer (ABC) in Russian clinical practice settings, as part of the PROSPERITY observational study. Materials and methods. At the date of the interim analysis (October 31, 2024), the PROSPERITY study had enrolled 2.390 patients with HR+/HER2– ABC receiving ribociclib, alpelisib, ET, or chemotherapy as part of standard clinical practice in Russia. The ribociclib group comprised 1.468 patients (61.4% of the total cohort). This article analyzes clinical and demographic characteristics, time to treatment failure (TTF), progression-free survival (PFS), overall survival (OS), time to chemotherapy (TTC), and the safety profile of ribociclib. The index date was defined as the date of initiation of ribociclib therapy during the study enrollment period. Results. The median age of patients in the ribociclib arm was 59.0 years. The majority of patients received ribociclib as first-line (63.0%) or second-line (21.9%) therapy. The median TTF was 17.2 months (95% CI 16.1–18.4), and the median PFS was 20.3 months (95% CI 18.8–21.5). Median PFS was 24.3 months for first-line therapy, 16.0 months for second-line, 13.4 months for third-line, and 8.6 months for fourth and subsequent lines. Median OS and median TTC were not reached. Adverse events (AEs) were reported in 47.5% (723/1522) of patients; the most common were neutropenia (16.2%) and leukopenia (7.4%). The rate of treatment discontinuation due to AEs was low (5.9% of all patients in the ribociclib arm). Conclusion. The observational PROSPERITY study provided real-world data from Russia demonstrating ribociclib effectiveness and safety profiles generally comparable to results previously obtained in pivotal clinical trials.

P A Herzen Journal of OncologyVol. 15(5)
Moscow Clinical Scientific Center (RU), Russian Cancer Research Center NN Blokhin (RU), Voronezh Regional Clinical Oncology Center (RU), Orlovsky Oncology Dispensary (RU), Republican Oncological Clinical Dispensary (RU), Tyumen Regional Oncological Dispensary (RU), Guz "Tul'skiy Oblastnoy Onkologicheskiy Dispanser (RU), State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU), State Budget Institution of Health St. Petersburg Clinical Research Center Specialized Types of Medical Care (RU), Moscow City Oncology Hospital №62 (RU), Government of the Khanty-Mansiysk Autonomous Okrug – Ugra (RU)
Good health and well-being
Openalex Percentile: Top 12%
Advanced Breast Cancer Therapies
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon